3月25日,嘉和生物-B(06998)发布公告,涉及非常重大收购事项,包括合并附属公司与标的公司之间的建议合并、反向收购、新上市申请、清洗豁免、股东人员留任计划、公司名称更改及增加法定股本等事项。公告指出,由于新上市申请需要包含公司及标的公司截至2024年12月31日的财务资料,双方需额外时间准备相关财务资料,并预计将在2025年4月底前提交新上市申请。此外,公告提到寄发通函的时间已延长至2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.